Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.970 -0.140 (-6.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death
Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non- 
Via Benzinga
US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Iovance Biotherapeutics Stock Is Jumping Today
Another Wall Street analyst has jumped aboard the Iovance train. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Is Marching Higher Today
Investors are excited by the prospects of a potential regulatory approval. 
Via The Motley Fool
Analyst Expectations for Iovance Biotherapeutics's Future
 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock. 
Via The Motley Fool
Crude Oil Gains Over 2%; PaxMedica Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Monday. The Dow traded up 0.34% to 35,064.42 while the NASDAQ rose 0.80% to 14,238.67. The S&P 500... 
Via Benzinga
Topics Stocks
Earnings Preview: Iovance Biotherapeutics
 
Via Benzinga
Why Shares of Iovance Biotherapeutics Jumped Monday
The company's stock rally began on Friday. 
Via The Motley Fool
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms. 
Via Benzinga
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
Via PressReach
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Four-year Analysis of C-144-01 Trial Cohorts 2 and 4 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Over $26M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. Newegg Commerce, Inc. (NASDAQ: NEGG) shares climbed 8.7% to... 
Via Benzinga
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
The approval process for the biotech's most advanced pipeline drug program is going quite well, it seems. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.